CEL-SCI (CVM) Competitors $2.49 -0.03 (-1.19%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$2.48 -0.01 (-0.24%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. GRCE, MRNS, MAAQ, ALLK, SXTC, INKT, RANI, SCYX, DYAI, and FBLGShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Grace Therapeutics (GRCE), Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Allakos (ALLK), China SXT Pharmaceuticals (SXTC), MiNK Therapeutics (INKT), Rani Therapeutics (RANI), SCYNEXIS (SCYX), Dyadic International (DYAI), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors Grace Therapeutics Marinus Pharmaceuticals Mana Capital Acquisition Allakos China SXT Pharmaceuticals MiNK Therapeutics Rani Therapeutics SCYNEXIS Dyadic International FibroBiologics CEL-SCI (NYSE:CVM) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Which has stronger valuation & earnings, CVM or GRCE? Grace Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$12.61-0.20Grace TherapeuticsN/AN/A-$9.57M-$0.89-3.52 Does the media prefer CVM or GRCE? In the previous week, CEL-SCI's average media sentiment score of 0.00 equaled Grace Therapeutics'average media sentiment score. Company Overall Sentiment CEL-SCI Neutral Grace Therapeutics Neutral Do analysts rate CVM or GRCE? Grace Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 283.39%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in CVM or GRCE? 12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 9.9% of CEL-SCI shares are held by company insiders. Comparatively, 13.5% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is CVM or GRCE more profitable? Grace Therapeutics' return on equity of -19.45% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% Grace Therapeutics N/A -19.45%-16.99% Which has more risk & volatility, CVM or GRCE? CEL-SCI has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. SummaryGrace Therapeutics beats CEL-SCI on 10 of the 11 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$7.55M$205.22M$5.56B$20.71BDividend YieldN/AN/A5.22%3.71%P/E Ratio-5.19N/A27.6628.10Price / SalesN/A223.65423.0038.31Price / CashN/A22.4436.8922.53Price / Book16.605.618.034.58Net Income-$26.92M-$96.61M$3.18B$985.54M7 Day Performance3.75%-0.57%2.93%2.79%1 Month Performance4.62%-3.74%1.72%4.37%1 Year Performance-93.14%10.50%34.39%15.08% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI0.0706 of 5 stars$2.49-1.2%N/A-93.1%$7.55MN/A-5.1943High Trading VolumeGRCEGrace Therapeutics1.7644 of 5 stars$2.93-2.3%$12.00+309.6%N/A$30.42MN/A-2.53N/AGap DownHigh Trading VolumeMRNSMarinus Pharmaceuticals2.3379 of 5 stars$0.55-0.2%$3.92+613.3%-54.2%$30.32M$30.99M-0.22110News CoverageMAAQMana Capital AcquisitionN/A$3.71-4.6%N/A+603.6%$30.14MN/A0.001ALLKAllakos2.8748 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190SXTCChina SXT Pharmaceuticals0.1382 of 5 stars$1.84flatN/A-78.1%$29.12M$1.93M0.0090News CoverageINKTMiNK Therapeutics3.2702 of 5 stars$7.48+3.0%$37.50+401.3%-25.3%$28.94MN/A-2.9730RANIRani Therapeutics1.5126 of 5 stars$0.49-2.1%$7.33+1,396.6%-85.6%$28.77M$1.03M-0.49110SCYXSCYNEXIS0.2634 of 5 stars$0.73-0.6%N/A-60.9%$28.65M$3.75M-1.3060DYAIDyadic International2.004 of 5 stars$0.94+2.9%$6.00+539.7%-35.3%$27.44M$3.49M-4.697News CoverageGap UpFBLGFibroBiologics2.2982 of 5 stars$0.72+3.6%$13.00+1,703.3%-87.0%$26.61MN/A-3.4310Gap Up Related Companies and Tools Related Companies Grace Therapeutics Competitors Marinus Pharmaceuticals Competitors Mana Capital Acquisition Competitors Allakos Competitors China SXT Pharmaceuticals Competitors MiNK Therapeutics Competitors Rani Therapeutics Competitors SCYNEXIS Competitors Dyadic International Competitors FibroBiologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
